Public disclosure of inside information according to article 17 MAR
Leverkusen (pta002/02.12.2021/01:05) - Leverkusen, Germany, December 2, 2021 - On November 29, 2021, Biofrontera AG (ISIN: DE0006046113) announced that its US subsidiary Biofrontera Inc. had entered into a private placement in the amount of USD 15 million (gross proceeds).
Today, Biofrontera Inc. (Nasdaq: BFRI) closed the private placement of 2,875,143 common shares and warrants with an institutional investor. The combined purchase price for one common share (or common share equivalent) with warrant is USD 5.25, priced at-the-market under Nasdaq rules. The warrants have an exercise price of $5.25 per share, will be immediately exercisable, and will expire five years from the issuance date.
As of today, following the successful closing of the private placement, Biofrontera AG holds approximately 52% shares in Biofrontera Inc.
Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
Tel: +49 (0214) 87 63 2 0, Fax: +49 (0214) 87 63 290
emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate
other stock exchanges: Nasdaq